Article: Nicotinamide Riboside and Pterostilbene Slow Disease Progression in ALS Patients: Clinical Findings

Jan 22, 2019 Amyotrophic Lateral Sclerosis (ALS) Clinical Neurological Health

Nicotinamide Riboside and Pterostilbene Slow Disease Progression in ALS Patients: Clinical Findings

Objectives

To assess the safety, tolerability, and efficacy of nicotinamide riboside and pterostilbene (NRPT) supplementation in people with amyotrophic lateral sclerosis (ALS).

Journal

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Key Outcomes

NRPT supplementation slowed ALS disease progression compared to placebo.
NRPT improved muscle strength, lung function, and body composition, as shown by increased skeletal muscle mass and reduced fat mass.

Duration

4 months

Dose

NRPT: 1200 mg

Study Design

Single-center, randomized, double-blind, placebo-controlled, parallel assignment study in 32 patients with ALS

See Published Study

Inflammation

Maternal Nicotinamide Riboside Supplementation Supports Postpartum Recovery and Offspring Brain Health: Preclinical Findings

Synopsis Metabolic stress can disrupt the balance of NAD+ molecules in the body. Nicotinamide riboside (NR) helps restore NAD+ levels and protect against such stress. This study tested whether NAD...